Takeda Presents Data at Virtual Scientific Congresses

Takeda Pharmaceutical Company Limited  (“Takeda”) today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 29-31 and the 25th Virtual Congress of the European Hematology Association (EHA), June 11-14.
“Takeda is committed to the research and development of new products that can help physicians address the needs of patients for whom few or no effective treatment options exist,” said Head, Oncology Therapeutic Area Unit, Takeda, Christopher Arendt.
“We look forward to presenting pipeline data from two late-stage compounds – pevonedistat and mobocertinib (TAK-788) – both of which have the potential to become transformative therapies to address unmet needs and improve the lives of patients. Additionally, data from our established hematology and lung medicines expand the understanding of efficacy and safety of our products in appropriate patient populations.”
Key data to be presented include:
Hematology Franchise and results about the Phase 2 Pevonedistat-2001 trial, interim analysis of the Phase 2 OPTIC trial with follow-up time of approximately 21 months, results from the Phase 3 TOURMALINE-MM4 trial evaluating NINLARO versus placebo as maintenance therapy for newly diagnosed multiple myeloma patients not treated with autologous stem cell transplantation (ASCT), evaluations from ALUNBRIG in both the TKI-naïve and TKI-resistant settings for patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) and date on mobocertinib, a small-molecule TKI specifically designed to selectively target epidermal growth factor receptor (EGFR) and HER2 exon 20 insertion mutations.


Please enter your comment!
Please enter your name here